These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20048433)

  • 41. [Uric acid and cardiorenal risk: marker or cause?].
    Bellomo G; Venanzi S; Timio M
    G Ital Nefrol; 2011; 28(2):157-65. PubMed ID: 21488030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
    Opie LH; Yusuf S; Kübler W
    Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hyperuricemia].
    Slot O
    Ugeskr Laeger; 1994 Apr; 156(16):2396-401. PubMed ID: 8009701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hyperuricemia as a risk factor of nephropathy in gout].
    Siniachenko OV; Diadyk AI; Nikolenko IuI; Vasilenko IV
    Ter Arkh; 1988; 60(1):97-101. PubMed ID: 3363519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
    Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H
    J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The serum uric acid and related cardiovascular risk factors in south Taiwan.
    Huang CC; Peng MC; Tsai WC; Chang YY; Chen WH; Chen SS; Liu JS
    Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):259-64. PubMed ID: 15906680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.
    Lin KC; Lin HY; Chou P
    J Rheumatol; 2000 Apr; 27(4):1045-50. PubMed ID: 10782835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical studies on hyperuricemia and gout after transplantation].
    Imanishi M; Ikegami M; Ishii T; Nishioka T; Uemura T; Kunikata S; Kanda H; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1990 Aug; 36(8):893-6. PubMed ID: 2239590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of hyperuricemia and gout in kidney and cardiovascular disease.
    Edwards NL
    Cleve Clin J Med; 2008 Jul; 75 Suppl 5():S13-6. PubMed ID: 18822470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of serum uric acid on blood-pressure lowering treatment.
    Grassi G
    Curr Med Res Opin; 2017 Nov; 33(sup3):15-19. PubMed ID: 28952389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
    Chen JH; Chuang SY; Chen HJ; Yeh WT; Pan WH
    Arthritis Rheum; 2009 Feb; 61(2):225-32. PubMed ID: 19177541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The problem of cardio-renal diseases in patients with gout.
    Ferri C
    Curr Med Res Opin; 2017 Nov; 33(sup3):9-13. PubMed ID: 28952391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived.
    Viazzi F; Leoncini G; Ratto E; Pontremoli R
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):510-8. PubMed ID: 16849905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.
    Johnson RJ; Kivlighn SD; Kim YG; Suga S; Fogo AB
    Am J Kidney Dis; 1999 Feb; 33(2):225-34. PubMed ID: 10023633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uric acid in heart disease: a new C-reactive protein?
    Krishnan E; Sokolove J
    Curr Opin Rheumatol; 2011 Mar; 23(2):174-7. PubMed ID: 21178630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
    Johnson RJ; Kang DH; Feig D; Kivlighn S; Kanellis J; Watanabe S; Tuttle KR; Rodriguez-Iturbe B; Herrera-Acosta J; Mazzali M
    Hypertension; 2003 Jun; 41(6):1183-90. PubMed ID: 12707287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers.
    Butler K; Teng R
    Clin Pharmacol Ther; 2012 Feb; 91(2):264-71. PubMed ID: 22190065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.